Gannex Pharma Co., Ltd., a unit of Ascletis Pharma Inc. (ASCLF.PK) Tuesday reported positive interim results from the Phase 2 study of its drug candidate ASC41 to treat patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).
In the Phase 2 study, patients are randomized to receive either ASC41 or placebo for 52-weeks. The interim analysis was conducted after 12-weeks.
At week 12, up to 93.3% patients who received ASC41, achieved at least a 30% relative reduction in liver fat content from baseline. The mean relative reduction in liver fat content from baseline was up to 68.2%.
Further, the company said adverse events were similar among patients receiving ASC41 treatment versus placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.